Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer

Clinical trial NCT06941987 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06941987
Sponsor: Shanghai Zhongshan Hospital
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL

Minimal Residual Disease Pancreatic Cancer Resectable

Start date: 2025-04-20
Primary completion: 2025-10-20
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.